"Covid-19 has brought so much uncertainty, but one certainty is that the vaccine race will generate winners and losers in the pharmaceutical and biotechnology industries. This will have a major impact on merger and acquisition activity. While the plethora of merger and acquisition deals are abundantly reported by the news media, there is a clear lack of in-depth analysis on the multiple rationales and various challenges in the life sciences industry. By offering contributions from a variety of experts inthe biotechnology and pharmaceutical industries, as well as experts on mergers and acquisitions, this edited collection will draw upon the knowledge of a variety of different actors within the fields of pharma and biotech. This book offers a timely exploration of the complexities of mergers and acquisitions in the pharmaceutical and biotechnology industries while seeking to bridge the gap between theory and practice. It presents a critical analysis of the rationale for acquisitions and studies the challenges of ensuring a successful deal. In the light of the Covid-19 pandemic, it will also explore the impact this may have on the industry, which may further stimulate mergers and acquisitions activity. It will be of interest to researchers, academics, policymakers, and students in the fields of strategy, management, governance, and the biotechnology and pharmaceutical industries"--
This book offers a holistic view of some of the key questions in M&As in the biotechnology and pharmaceutical industries whilst attempting to bridge the gap between theory and practice.
Covid-19 has brought so much uncertainty, but one certainty is that the vaccine race will generate winners and losers in the pharmaceutical and biotechnology industries. This will have a major impact on merger and acquisition activity. While the plethora of merger and acquisition deals are abundantly reported by the news media, there is a clear lack of in-depth analysis on the multiple rationales and various challenges in the life sciences industry. By offering contributions from a variety of experts in the biotechnology and pharmaceutical industries, as well as experts on mergers and acquisitions, this edited collection will draw upon the knowledge of a variety of different actors within the fields of pharma and biotech. This book offers a timely exploration of the complexities of mergers and acquisitions in the pharmaceutical and biotechnology industries while seeking to bridge the gap between theory and practice. It presents a critical analysis of the rationale for acquisitions and studies the challenges of ensuring a successful deal. In the light of the Covid-19 pandemic, it will also explore the impact this may have on the industry, which may further stimulate merger and acquisition activity. It will be of interest to researchers, academics, policymakers, and students in the fields of strategy, management, governance, and the biotechnology and pharmaceutical industries.
Chapter 1: Introduction: Taking stock of the wave of M&As in the life
sciences industry. What has the past decade taught us? Part 1: The Pre-merger
Phase
Chapter 2: The Art of Letting Go: Corporate Divestitures in the
Bio-Pharmaceutical Industries
Chapter 3: Preventive & Active takeover defense
strategies in the Pharmaceutical and Biotechnology Industries
Chapter 4:
Merger & Acquisition trends in the Gene Therapy sector
Chapter 5: Risk
management in pharmaceutical and biotechnology mergers and acquisitions Part
II: The Transaction Phase
Chapter 6: Finding the right fit during the M&A
process
Chapter 7: Exploring all options: unconventional acquirers in the
healthcare sector
Chapter 8: To make it or buy it: Investing in M&A or R&D as
contradictory or complementary strategies in the biotech and pharma
industries
Chapter 9: Should governments get involved in Big Pharma Mergers &
Acquisitions? Part III: The Post-Deal Integration Phase
Chapter 10: A tale of
two masters. Assessing the post-acquisitions management strategies of private
equity firms and industrial pharmaceutical groups
Chapter 11:
Post-acquisition challenges in the wake of the Covid-19 pandemic in the
pharmaceutical and biotech industry
Chapter 12: Depth in biotech & pharma
merger and acquisitions. How much should you integrate? A multi-case
analysis.
Chapter 13: What is the right speed for post-acquisition
integration within the pharmaceutical & biotechnology industries?
Chapter 14:
Conclusion: Future Perspectives in Pharmaceutical and Biotechnology mergers
and acquisitions
Mark Thomas is Associate Dean for Programmes and Associate Professor of Strategic and Management at ICN Business School, France. He has taught Corporate Strategy and Leadership at Master and Executive Education levels including the Advanced Masters degree in Biotechnology and Pharmaceutical Management at Grenoble EM.
He holds a PhD from Lancaster University Management School, UK. His research focuses on the change management process during post-merger integration. He also holds an MSc in Strategy and Management from Em-lyon, France and is a graduate of Harvard Business School.
Janna Rose is a professor in People, Organizations and Society at Grenoble Ecole de Management (GEM) in France. While her teaching focuses mainly on ethics and social responsibility, as well as laboratory management and innovation, she has served as a coordinator for the Chair for Public Trust in Health and a member of the ethics board (ELSI) for EIT Health projects across Europe. Previously, she worked as a technician and manager in genomics and phytochemistry laboratories before earning degrees in Medical Anthropology (MA, Tulane University) and in Ethnobotany (PhD, Florida International University).
Daugiau apie elektronines knygas